Time to tackle the blood‐brain barrier in <i>HER2</i>‐mutant lung cancer

Lin, Jessica J.; Gainor, Justin F.

doi:10.1002/cncr.32460

Cited by 3 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These studies highlighted the importance of developing HER2 -targeted agents with higher ability to penetrate the blood-brain barrier. 25 Moreover, lung adenocarcinomas with HER2 mutations exhibit a more aggressive behavior on enhanced computed tomography compared with KRAS - and EGFR -mutant controls, and show a more frequent nodal metastatic spread compared with KRAS -mutant controls. 26 A case report described a lung adenocarcinoma patient with lymphangitic spread and psammoma bodies harboring an HER2 exon 20 insertion mutation.…”

Section: Consensus On Her2 Alterations In Nsclcmentioning

confidence: 99%

Consensus for HER2 alterations testing in non-small-cell lung cancer

et al. 2022

View full text Add to dashboard Cite

Human epidermal growth factor receptor 2 (HER2) is a transmembrane glycoprotein receptor with intracellular tyrosine kinase activity. Its alterations, including mutation, amplification and overexpression, could result in oncogenic potential and have been detected in many cancers such as non-small-cell lung cancer (NSCLC). Such alterations are, in general, considered markers of poor prognosis. Anti-HER2 antibody-drug conjugates, e.g. trastuzumab deruxtecan (T-DXd, DS-8201) and disitamab vedotin (RC48), were recently approved for HER2-positive breast and gastric cancers. Meanwhile, several HER2-targeted drugs, such as T-DXd, neratinib, afatinib, poziotinib and pyrotinib, have been evaluated in patients with advanced NSCLC, with several of them demonstrating clinical benefit. Therefore, identifying HER2 alterations is pivotal for NSCLC patients to benefit from these targeted therapies. Recent guidelines on HER2 testing were developed for breast and gastric cancer, however, and have not been fully established for NSCLC. The expert group here reached a consensus on HER2 alteration testing in NSCLC with the focus on clinicopathologic characteristics, therapies, detection methods and diagnostic criteria for HER2-altered NSCLC patients. We hope this consensus could improve the clinical management of NSCLC patients with HER2 alterations.

show abstract

Section: Consensus On Her2 Alterations In Nsclcmentioning

confidence: 99%

Consensus for HER2 alterations testing in non-small-cell lung cancer

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Similar to NSCLC patients with EGFR mutation and ALK gene arrangement, HER2-mutated NSCLC patients do not benefit from immunotherapy. Lin et al 59 suggested that the tumor microenvironment lacking CD8+ T cell infiltration may explain the poor efficacy of ICIs in the treatment of EGFR and HER2-driven NSCLC.…”

Section: Her2 Mutation In Nsclcmentioning

confidence: 99%

Progress in Treatment of Non-Small Cell Lung Cancer Harboring HER2 Aberrations

Ni¹,

Zhang²

2021

OTT

View full text Add to dashboard Cite

Epidermal growth factor receptor 2 (HER2/ErbB2/neu), a member of ErbB receptor tyrosine kinase family, forms homo-or heterodimers with ErbB1 (HER1/EGFR), ErbB3 (HER3), or ErbB4 (HER4), to activate signal transduction pathways and promote proliferation, differentiation and tumorigenesis. Preliminary clinical trials of monoclonal antibodies, antibody conjugates and small-molecule tyrosine kinase inhibitors targeting HER2 have indicated that HER2 is a potential therapeutic target in non-small cell lung cancer (NSCLC). HER2 aberrations in NSCLC patients mainly include mutation, amplification, and overexpression. While there are significant differences in the outcome of NSCLC with these HER2 changes, no consensus has been reached for the incidence, detection method and targeted treatments for the three types of HER2 aberration. HER2 mutation is generally considered to have more clinical relevance and response to HER2-targeted therapies. In this review, we discuss HER2 alterations in NSCLC, including diagnostic challenges and treatment strategies particular to the HER2 mutation.

show abstract

“…Several studies have suggested potential differences in the frequencies of brain metastases across the different oncogenic drivers in NSCLC[ 85 ]. NSCLC harboring alterations in EGFR, ALK , or ROS1 have been associated with increased frequencies of brain metastases[ 86 - 89 ].…”

Section: Patterns Of Nodal and Distant Metastasesmentioning

confidence: 99%

Role of imaging biomarkers in mutation-driven non-small cell lung cancer

Mendoza

Piotrowska

Lennerz

et al. 2020

WJCO

View full text Add to dashboard Cite

Lung cancer remains the leading cause of cancer-related deaths worldwide. The treatment of non-small cell lung cancer (NSCLC), which accounts for a vast majority of lung cancers, has shifted to personalized, targeted therapy following discoveries of several targetable oncogenic mutations. Targeting of specific mutations has improved outcomes in many patients. This success has led to several target-specific agents replacing chemotherapy as first-line treatment in certain mutated NSCLC. Several researchers have reported that there may be imaging biomarkers that may be predictive of the presence of these mutations. These features, when present, have the potential in triaging patients into the most appropriate diagnostic and treatment algorithms. Distinct imaging features and patterns of metastases that have been associated with NSCLC with various targetable oncogenic mutations are presented in this review.

show abstract

Time to tackle the blood‐brain barrier in HER2‐mutant lung cancer

Cited by 3 publications

References 23 publications

Consensus for HER2 alterations testing in non-small-cell lung cancer

Consensus for HER2 alterations testing in non-small-cell lung cancer

Progress in Treatment of Non-Small Cell Lung Cancer Harboring HER2 Aberrations

Role of imaging biomarkers in mutation-driven non-small cell lung cancer

Contact Info

Product

Resources

About